Secukinumab Loss of Efficacy Is Perfectly Counteracted by the Introduction of Combination Therapy (Rescue Therapy): Data from a Multicenter Real-Life Study in a Cohort of Italian Psoriatic Patients That Avoided Secukinumab Switching

• Main Authors: Giovanni Damiani (Author), Giulia Odorici (Author), Alessia Pacifico (Author), Aldo Morrone (Author), Rosalynn R. Z. Conic (Author), Tima Davidson (Author), Abdulla Watad (Author), Paolo D. M. Pigatto (Author), Delia Colombo (Author), Piergiorgio Malagoli (Author), Marco Fiore (Author)
• Format: Book
• Published: MDPI AG, 2022-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Since psoriasis (PsO) is a chronic inflammatory disease, patients may experience a drug failure also with very effective drugs (i.e., secukinumab) and, consequently, dermatologists have two therapeutic options: switching or perform a combination therapy (rescue therapy) to save the drug that had dec...